Evidence map›Paper›PMID 35147584›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2022

SARS-CoV-2 Booster Vaccination for Participants in "HIV Cure"-Related Clinical Trials.

Michael J Peluso, Meghann C Williams, Danielle M Campbell, Lynda Dee, Jeff Taylor, Lynn H Ngo, Rebecca Hoh, Karine Dubé, John A Sauceda, Steven G Deeks

Open access · greenAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Long COVID and rheumatology: Clinical, diagnostic, and therapeutic implications.Best practice & research. Clinical rheumatology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Michael J PelusoDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA.
Meghann C WilliamsDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA.
Danielle M CampbellDelaney AIDS Research Enterprise (DARE) Community Advisory Board.
Lynda DeeDelaney AIDS Research Enterprise (DARE) Community Advisory Board.
Jeff TaylorMartin Delaney Collaboratory Community Advisory Board.
Lynn H NgoDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA.
Rebecca HohDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA.
Karine DubéGillings School of Public Health, University of North Carolina (UNC), Chapel Hill, NC.
John A SaucedaCenter for AIDS Prevention Studies (CAPS), University of California, San Francisco, CA.
Steven G DeeksDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA.
University of California, San Francisco · USDelaney AIDS Research Enterprise · USDesert AIDS Project · US

Funding

Delaney AIDS Research Enterprise to Cure HIVUM1AI126611 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT, PICKER, LOUIS J. · 2016 to 2020
$27.9M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
Training Program for Scientists Conducting Research to Reduce HIV Health DisparitR25MH067127 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Emily A Arnold, Torsten Brian Neilands · 2003 to 2026
$5.4M
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinicR01AI158013 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, SPINELLI, MATTHEW A. · 2020 to 2023
$3.1M
Characterizing the virologic and immunologic signatures of HIV exceptional controlK23AI157875 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PELUSO, MICHAEL JOSEPH · 2021 to 2025
$927k
Pilot Integration of Participant-Centered Outcomes in HIV Cure Research in the United States: Implications for Ethical ConductR21MH118120 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUBE, KARINE · 2019 to 2020
$566k
Evaluation of the Impact of HIV Status on the Immune Response to mRNA COVID-19 VaccinesR21AI167648 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, SPINELLI, MATTHEW A. · 2022 to 2023
$444k
NIAID NIH HHS K23 AI157875NIAID NIH HHS L30 AI147159NIAID NIH HHS R01 AI158013NIAID NIH HHS R21 AI167648NIAID NIH HHS T32 AI060530NIAID NIH HHS UM1 AI126611NIMH NIH HHS R21 MH118120NIMH NIH HHS R25 MH067127
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19HIV InfectionsAntibodies, ViralClinical Trials as TopicHumansSARS-CoV-2VaccinationAntibodies, Viral

Identifiers

PMID35147584
PMCPMC8851852
OpenAlexW4200093243

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.